There’s some interesting news from Mercia Asset Management, the proactive specialist asset management business which provides venture, private equity or debt finance to regional businesses with growth ambitions.
Just 3-months after selling Native Antigen Company for 8.6x cost, from which Mercia won Best EIS Exit 2020 at the EISA 2020 Awards announced last week, the EIS has exited the EIS portfolio company Clear Review for 8.0x cost, and an impressive 122% IRR.
This exit is indicative of the maturation of the Mercia EIS portfolio. The company reports that it is working on at least another five realisations, at multiples of between 1.5x and 25x cost. Further details will be announced in due course.
